Search
# Popular search #
0%
# Popular search #
Stock Code
603087.SHGan & Lee Pharmaceuticals Announces the Approval for the Insulin Pen in Thailand
Gan & Lee Pharmaceuticals Begins First-In-Human Trial in the U.S. for Investigational Drug, GZR18
Mike Hu to join Gan & Lee Pharmaceuticals as Chief Executive Officer and President of Gan & Lee USA
Gan & Lee Pharmaceuticals Begins First In-Human Trial in China for Investigational Compound, GZR18
New Data on Phase 1 Proposed Biosimilar Gan & Lee Insulins Aspart (GL-ASP), Lispro (GL-LIS), and Glargine (GL-GLA) Presented at the American Diabetes Association’s 81st Scientific Sessions
Gan & Lee Pharmaceuticals Concludes Phase 3 Studies of Gan & Lee Insulin Glargine (GL-GLA)
To be a world-class pharmaceutical company with focus on global business development
Our products have been approved in 18 countries
Our products have been exported to 14 countries
Our products have been studied in clinical trials in 12 countries
Our products have been approved in 18 countries
Our products have been exported to 14 countries
Our products have been studied in clinical trials in 12 countries
This website uses cookies to give users like yourself the best possible content and experience. For more information about your choices regarding cookies, please review our Privacy Policy .
The site you are about to visit is maintained by a third party who is responsible for its content.
This link is provided on the Gan & Lee website as a service to our visitors. Gan & Lee is not responsible for the privacy policy of any third-party websites. Gan & Lee encourages visitors to read the privacy policy of every website that you may visit.
